Trending News

Get Your Daily Dose of Trending News

Health

Omicron: What We Know About the New Covid Variant

[ad_1]

First identified in Botswana and South Africa in November, this new iteration of the coronavirus has prompted concern among scientists and public health officials because it carries an unusually high number of mutations that make it more transmissible and less susceptible to existing vaccines.

On Nov. 26, the World Health Organization designated Omicron a “variant of concern” and warned that the global risks posed by it were “very high,” despite what officials described as a multitude of uncertainties. Since then, the variant has been identified in nearly 60 countries, according to the W.H.O., on every continent except Antarctica. At the beginning of December, a California resident who returned home from South Africa was identified as the first American infected with Omicron. Officials have since detected the variant in 27 states.

It’s too early to say how widespread the variant will become in the United States. But experts like Dr. Rochelle Walensky, director of the Centers for Disease Control and Prevention, cautioned that the number is likely to markedly increase in the coming weeks.

On Dec. 10, the C.D.C. released a report on the first 43 cases identified in the United States. Only about one-third of those infected with Omicron had traveled internationally in the two weeks before testing positive or developing symptoms. That finding indicated that Omicron was already spreading within the United States from person to person.

In the first days after Omicron’s discovery, scientists could not say much about Omicron’s threat. They could see that it had mutations shown in other variants to speed up their transmission and allow them to partially evade immune responses. But they had to wait for more evidence to emerge to get a clearer picture of its nature.

Within a few weeks, early results of studies started coming to light. While some uncertainties remained, this evidence made it clear that Omicron poses a serious threat worldwide. “It rules out some of the rosier futures,” said William Hanage, an epidemiologist at the Harvard T.H. Chan School of Public Health.

Not very well. One reason that the Omicron-driven surge in South Africa was so surprising is that the country had already experienced extensive waves of Covid caused by earlier variants. As the result, the majority of South Africans had been infected at some point in the pandemic. Despite that immunity, a large number of South Africans have become infected once more with Omicron.

British researchers found similar results in a study they published on Dec. 10. They found that many people with Omicron had already had survived Covid. The researchers estimated that the risk of reinfection with Omicron is about five times greater than that for other variants.

This ability to evade immune defenses is probably part of the explanation for why Omicron cases are doubling so quickly. While other variants are getting knocked out by antibodies, Omicron is succeeding in infecting more cells — making it more successful at getting into more people.

When Omicron surfaced in South Africa, only 30 percent of the country’s population had been vaccinated. That low vaccination rate made it difficult to determine how effective vaccines were against Omicron. Researchers at vaccine companies and academic labs quickly launched laboratory studies to get some clues.

They mixed antibodies from vaccinated people with Omicron viruses in Petri dishes of human cells. Then they waited to see how well the antibodies blocked the viruses from replicating.

The first batch of experiments came to the same basic conclusion: Antibodies from the Pfizer-BioNTech vaccine were much less successful at stopping Omicron than they were against earlier variants. But people who got a third booster shot produced much higher levels of antibodies, which do a better job fighting Omicron.

Early epidemiological studies arrived at similar conclusions. In Britain, researchers found that after six months, two doses of the AstraZeneca vaccine provided no protection at all from infection from Omicron. Two doses of Pfizer-BioNTech had an effectiveness of just 34 percent. But a Pfizer-BioNTech booster had an effectiveness of 75 percent against infection.

These results have reinvigorated vaccination efforts and spurred widespread booster campaigns in many countries to prepare for Omicron surges in the weeks to come.

Scientists strongly suspect this will be the case, but they need more direct evidence to know for sure.

In addition to producing antibodies to coronaviruses, the vaccines also stimulate the growth of T cells that help fight the disease. T cells learn to recognize when other cells are infected with coronaviruses and then destroy them, slowing the infection. The mutations that allow Omicron to evade antibodies are not expected to let it escape the recognition of T cells.

If this turns out to be the case, scientists expect that Omicron will be very good at causing infections in vaccinated people, but will be much less likely to advance to severe disease. The result would be more mild to moderate cases, with fewer hospitalizations. Boosters will likely be even more effective at preventing severe disease.

The early Omicron cases raised hopes that the variant might cause milder disease than other variants. But it’s too soon to know if that’s true.

In South Africa, where Omicron created its first known surge, doctors reported seeing fewer severe cases than in earlier waves of Covid. In fact, they often only became aware that their patients were infected with the coronavirus after they were admitted for other conditions.

But disease projections are not carved in stone. The variables can change if more people get vaccinated and practice safety measures in public like social distancing and mask-wearing that help contain the spread. Boosters will create an even stronger wall of defense.

Some governments are already taking further actions to fight Omicron. Denmark, for example, sent students home on Dec. 10, closed bars and took other measures to reduce crowds. And Britain has reimposed several measures, and encouraged citizens to work from home.

When the W.H.O. began to name emerging variants of the coronavirus, they turned to the Greek alphabet — Alpha, Beta, Gamma, Delta and so on — to make them easier to describe. The first “variant of concern,” Alpha, was identified in Britain in late 2020, soon followed by Beta in South Africa.

But veterans of American sorority and fraternity life might have noticed the system has skipped the next two letters in the alphabetical order: Nu and Xi.

Officials thought Nu would be too easily confused with “new,” but the next letter, Xi, is a bit more complicated. W.H.O. officials said it was a common last name, and therefore potentially confusing. Some noted that it is also the name of China’s top leader, Xi Jinping.

A spokesman for the W.H.O. said the organization’s policy was designed to avoid “causing offense to any cultural, social, national, regional, professional, or ethnic groups.”

Next in line? Omicron. (Here’s how it’s pronounced, and here.)

Emily Anthes contributed to this article.

[ad_2]

Sahred From Source link Health

Leave a Reply

Your email address will not be published. Required fields are marked *